JP2015506696A - ＴＧＦ−β２発現を抑制するｓｈＲＮＡ - Google Patents

ＴＧＦ−β２発現を抑制するｓｈＲＮＡ Download PDF

Info

Publication number
JP2015506696A
JP2015506696A JP2014555484A JP2014555484A JP2015506696A JP 2015506696 A JP2015506696 A JP 2015506696A JP 2014555484 A JP2014555484 A JP 2014555484A JP 2014555484 A JP2014555484 A JP 2014555484A JP 2015506696 A JP2015506696 A JP 2015506696A
Authority
JP
Japan
Prior art keywords
shrna
tgf
adenovirus
seq
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014555484A
Other languages
English (en)
Japanese (ja)
Inventor
ジェ・ジン・ソン
ジョ・ハン・キム
セ・ウン・オー
Original Assignee
インダストリー−アカデミック・コーポレーション・ファウンデーション・ヨンセイ・ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インダストリー−アカデミック・コーポレーション・ファウンデーション・ヨンセイ・ユニヴァーシティ filed Critical インダストリー−アカデミック・コーポレーション・ファウンデーション・ヨンセイ・ユニヴァーシティ
Priority claimed from PCT/KR2013/000791 external-priority patent/WO2013115579A1/ko
Publication of JP2015506696A publication Critical patent/JP2015506696A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014555484A 2012-01-31 2013-01-31 ＴＧＦ−β２発現を抑制するｓｈＲＮＡ Pending JP2015506696A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20120009811 2012-01-31
KR10-2012-0009811 2012-01-31
KR10-2013-0010233 2013-01-30
KR1020130010233A KR101420564B1 (ko) 2012-01-31 2013-01-30 ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
PCT/KR2013/000791 WO2013115579A1 (ko) 2012-01-31 2013-01-31 ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ

Publications (1)

Publication Number Publication Date
JP2015506696A true JP2015506696A (ja) 2015-03-05

Family

ID=49215002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555484A Pending JP2015506696A (ja) 2012-01-31 2013-01-31 ＴＧＦ−β２発現を抑制するｓｈＲＮＡ

Country Status (3)

Country Link
JP (1) JP2015506696A (zh)
KR (1) KR101420564B1 (zh)
CN (1) CN104245936B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101713407B1 (ko) * 2014-03-31 2017-03-07 연세대학교 산학협력단 아데노바이러스 감염 및 복제가 가능한 흑색종 세포주
WO2015152609A1 (ko) * 2014-03-31 2015-10-08 연세대학교 산학협력단 ＧＭ－ＣＳＦ 유전자; 데코린 유전자; ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ; 및 ＦｏｘＰ３ 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물
JP6898325B2 (ja) * 2015-12-08 2021-07-07 ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ ＧＭ−ＣＳＦ遺伝子；Ｆｌｔ３Ｌ−ＴＲＡＩＬ融合遺伝子；ＴＧＦ−βの発現を抑制するｓｈＲＮＡ；およびＨＳＰ発現を抑制するｓｈＲＮＡを含む抗腫瘍組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154542A1 (en) * 2010-06-11 2011-12-15 Artisense Pharma Gmbh Method for selective oligonucleotide modification

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674210A1 (en) * 2005-12-30 2007-07-12 Intradigm Corporation Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
CN101974529B (zh) * 2010-09-21 2013-04-03 南京大学（苏州）高新技术研究院 含自由三磷酸基团的TGF-β特异性siRNA及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154542A1 (en) * 2010-06-11 2011-12-15 Artisense Pharma Gmbh Method for selective oligonucleotide modification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015033218; Ｃａｎｃｅｒ　Ｒｅｓ，　２００９，　ｖｏｌ．６９，　ｎｏ．３，　ｐ．８２８-８３５ *
JPN6015033222; ｓｉＤｉｒｅｃｔ　ｖｅｒｓｉｏｎ　２．０　ｈｉｇｈｌｙ　ｅｆｆｅｃｔｉｖｅ，　ｔａｒｇｅｔ　ｓｐｅｃｉｆｉｃ　ｓｉＲＮＡ　ｏｎｌｉｎｅ　ｄｅｓｉｇｎ　ｓｉｔｅ ２００９，　［Ｒｅｔｒｉｅｖｅｄ　ｏｎ　Ａｕｇｕｓｔ　１３，　２０１５］, ＵＲＬ：ｈｔｔｐ：／／ｓｉｄｉｒｅｃｔ２．ｒｎａｉ．ｊｐ／ *

Also Published As

Publication number Publication date
KR20130088792A (ko) 2013-08-08
KR101420564B1 (ko) 2014-07-17
CN104245936B (zh) 2016-04-06
CN104245936A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
CN107406852B (zh) 用于莱伯氏先天性黑蒙的寡核苷酸疗法
JP5383186B2 (ja) Ｈ１９をダウンレギュレートする核酸薬剤、及びそれを使用する方法
EP2850184A1 (en) Compositions and methods for modulating gene expression
US20100086526A1 (en) Nucleic acid constructs and methods for specific silencing of h19
US11304970B2 (en) EGFR gene expression-suppressing siRNA, precursor of same, and applications thereof
US9222090B2 (en) RNA interference target for treating AIDS
CN109563513B (zh) 一种抑制K-RAS基因表达的siRNA及其前体和应用
CN113694077A (zh) 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
CN111876421A (zh) 靶向KrasG12D突变转录本的gRNA序列、载体及其应用
JP2015506696A (ja) ＴＧＦ−β２発現を抑制するｓｈＲＮＡ
JP2018109058A (ja) Ｈｐｖ感染に係わる癌の治療用組成物
JP2022524434A (ja) Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用
KR101286053B1 (ko) ＴＧＦ－β１ 발현을 억제하는 ｓｈＲＮＡ
KR101374585B1 (ko) ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ
WO2021218802A1 (zh) 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
US11498976B2 (en) Viral complex comprising shRNA and anti-EpCAM antibody and uses thereof
CN115927472A (zh) 一种抗vegf抗体体内表达系统的构建和应用
KR101683964B1 (ko) Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터
WO2013115579A1 (ko) ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
JP4505566B2 (ja) 肺癌治療剤
CN107184984A (zh) Rpl10的抑制剂在制备治疗卵巢癌的药物中的应用
US20210332364A1 (en) siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
US20150111952A1 (en) Method for treating glioma using tarbp2 expression inhibitor
JP2010521460A (ja) 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制
WO2023023597A1 (en) Virus-like particle

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160201